Here’s my take on why it’s important to address weight loss for reducing the risk of comorbidities in patients with type 2 diabetes and the role of GLP-RAs and SGLT2 inhibitors in amplifying a healthier lifestyle.
Here’s my take on the inclusion of a dual GIP/GLP-1 receptor agonist in the therapy selection decision-making process for patients with T2D, considering both their comorbidities and their priorities.
Here’s my take on strategies to collaborate with patients on their journey to achieve their weight loss goals.
Learn about current clinical approaches to T2D management and the selection of therapies that provide benefits for patients with relevant comorbidities, including weight management as a primary treatment target, while improving hyperglycemia.
Learn about current clinical approaches to T2D management and the selection of therapies that provide benefits for those with relevant comorbidities, as well as the importance of using shared decision-making strategies with patients.